Business

Biotech M&A Boom

Updated 2026-06-04 06:05 UTC 1 source Neutral

The biotechnology sector is experiencing a strong year for mergers and acquisitions. This is driven by patent expirations, buoyant public markets, and pharmaceutical companies seeking to expand their pipelines.

Coverage timeline — 1 article

CNBC

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

2026-06-04 05:45 UTC